Phase III MIRASOL (GOG 3045/ENGOT-ov55) study: Initial report of mirvetuximab soravtansine vs. investigator's choice of chemotherapy in platinum-resistant, advanced high-grade epithelial ovarian, primary peritoneal, or fallopian tube cancers with high folate receptor-alpha expression

Kathleen N. Moore, Antoine Angelergues,Gottfried E. Konecny,Susana N. Banerjee,Sandro Pignata,Nicoletta Colombo,John William Moroney,Casey Cosgrove,Jung-Yun Lee, Andrzej Roszak, Shani Breuer, Jacqueline Maria Tromp, Diana Bello-Roufai,Lucy Gilbert,Rowan Miller, Tashanna K. N. Myers, Yuemei Wang,Anna Berkenblit,Domenica Lorusso,Toon Van Gorp

JOURNAL OF CLINICAL ONCOLOGY(2023)

引用 0|浏览27
暂无评分
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要